April 8, 2025 8:09am

However, its strength is still perpendicular as tariff gusts are easing

The rising Treasury yields are a strong indication that recession fears had become overblown, and perhaps the expectation that the Fed will not be making any emergency cuts. It also may be that Trump’s strategy will not turn out to be as destructive as the bears insist, they are.”  Louis Navellier, CIO of Navellier & Associates>

Pre-open Indications: 7 Positive and 1 Negative Indications

I was once told by a “very” prominent figure early in my career, “write it right, keep it tight without hype and never lose the stride to guide the reader - me” – they were pretty simple instructions to follow!

No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief 

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!

 

Monday’s night’s … RegMed Investors (RMi) Closing Bell: swing low, not so sweet chariot … https://www.regmedinvestors.com/articles/13870

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN), The chokehold got tighter cutting-off any capacity to lift multiple going concern at-risk marker … https://www.regmedinvestors.com/articles/13812

 

Tuesday: The pre-open Dow futures are UP +2.90% or (+1,107 points), the S&P futures UP +2.73% or (+139.25 points) and the Nasdaq futures are UP +2.57% or (+450.75 points)

  • Stock futures bounced on Tuesday, 4/8
  • European markets moved +2% higher at mid-day,
  • Asia Pacific markets traded higher after previous session’s steep losses.

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

Monday: The Dow closed DOWN -349.26 points or -0.91%, the S&P closed DOWN -11.83 points or -0.23% while the Nasdaq close UP +15.48 points or +0.10%

Market participants traded about 29 billion shares on Monday, resulting in the highest volume day in at least 18 years, according to FactSet and Nasdaq Trader. <CNBC>

Economic Data Docket: National Federation of Independent Business will issue its small business index reading for March

 

Q2- April – 4 negative and 1 positive closes

  • Q1/25 – March, 10 positive and 11 negative closes
  • February – 12 holiday, 11 negative and 7 positive closes
  • January - 2 holidays, 1 market close, 10 negative and 10 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.

A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • Better part of valor to not lead any investor to temptation; I am partially passing on forecasting the daily indications as to expectation while the aftermarket blanked while the pre-open waits for the …  econs, it is still a mix of ups, downs and just uncertainty

Although … trending tickers 

Negative Indications:

  • AxoGen (AXGN) closed up +0.40 after Friday’s -$0.82 with a negative -$0.37 or -2.23% pre-market

Positive Indications:

  • Alnylam Pharmaceuticals (ALNY) closed down -$2.79 after Friday’s -$26.42 with a positive +$1.66 or +0.71% pre-market
  • Beam Therapeutics (BEAM) closed up +$0.03 after Friday’s -$1.19 with a positive +$0.63 or +4.15% pre-market
  • CRISPR Therapeutics (CRSP) close down -$0.27 after Friday’s -$0.01 with a positive +$0.70 or +2.16% pre-market
  • Intellia therapeutics (NTLA) closed down -$0.09 with a positive +$0.34 or +3.67% pre-open
  • Ionis Pharmaceuticals IONS) closed up +$0.48 after Friday’s -$1.43 with a positive +$0.73 or +2.65% pre-market
  • Moderna (MRNA) close up +$0.53 with a positive +0.53 or +2.07% pre-open
  • Ultragenyx Pharmaceuticals (RARE) closed down -$0.29 after Friday’s -$2.70 with a positive +$0.52 or +1.62% pre-market

 

The BOTTOM LINE:   Maintaining, “I think speculative behavior in this current market is … lowering emotion to common sense.”

Merger and acquisition (M&A) activity; sector companies will seek opportunities to sell to better financed companies that can "deal with these additional costs associated of R&D and escalating SG&A.”

NOT much has changed, as I have written, “uncle algo and his trading dwarfs” determine the heights or lows of share pricing”

What could 2025 have in store for the capital access space as Partners are the gift of life!

  • "You'll see a number of cell and gene therapy comandantes NEED for financings – they’re desperate for cash, but I do think a lot of cell and gene therapy sector companies NEED to be focused on what is driving their own growth —they're focused on a lot of change BUT … that's happening in the market… capital expansion is second.

I seem to be asking a question followed by a question …

  • Do we need to brace ourself for more economics and their down trending affect?

Welcome to my world of defining the “grey’ in our universe!

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.